- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Sa | FTC clears Bristol-Myers' $74B deal to buy Celgene - but Dems signal a potential hard shift against Big Pharma M&A | ||
| Fr | Novartis scores its latest FDA OK - this time for a new sickle cell disease drug picked up in a $665M deal | ||
| Fr | AstraZeneca gains EU nod for diabetes triple; Amgen and Duke launch real-world PCSK9 observational study | ||
| Fr | Five drugs, including two Novartis therapies, win EMA endorsement | ||
| Fr | Atomwise's X-37 spinout gets $14.5 million to launch AI discovery efforts | ||
| Fr | Abbott Laboratories CEO Miles White passes baton down to successor; Lonza CEO Marc Funk hits the exit | ||
| Fr | UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA | ||
| Fr | EMA finalizes clinical development guideline for new gout treatments | ||
| Fr | Roche bags 'breakthrough' anti-fibrosis drug in $1.4B biotech buyout deal | ||
| Fr | Novartis spinout's first anti-aging PhIII is a flop, so now they'll turn to Parkinson's challenge as shares wilt | ||
| Fr | Preparing for new wave of treatments, Fujifilm drops $55 million for gene therapy center | ||
| Fr | After positive panel vote, Shionogi antibiotic scores US approval | ||
| Do | UPDATED: China's BeiGene scores first-ever FDA approval - but can they carve up J&J's blockbuster franchise? | ||
| Do | Amarin emerges from an expert panel review with a clear endorsement for Vascepa and high odds of success when the FDA weighs in formally | ||
| Do | What does $62B buy you these days? A lot, says Takeda execs as the pharma player promises a blockbuster R&D future | ||
| Do | Shorts galore: Muddy Waters sees slide for PeptiDream, tweets concerns about FibroGen's new data | ||
| Do | BioMarin breaks out positive PhII achondroplasia data; Thermo Fisher opens 'customer solutions' facility in China | ||
| Do | Sarepta picks up a slate of preclinical gene therapy programs, seeding new StrideBio deal with $48M upfront | ||
| Do | Pincer movement: California biotech gets $35M to suffocate cancer in coordinated attack | ||
| Do | Little biotech's stock flatlines as its followup attempt at a depression drug trial win ends in another defeat | ||
| Do | Allergan enlists Exicure in search of hair loss drugs with $25M upfront, doubling down on area dear to AbbVie | ||
| Do | AstraZeneca, Merck win red carpet treatment at the FDA as a 3-time loser seeks speedy OK for rare tumors | ||
| Do | FDA panel largely opposes expanding use of Lilly, Boehringer's SGLT2 inhibitor to type 1 diabetics | ||
| Do | Bayer bets up to $100M on exploring new biomolecular condensate terrain with a biotech upstart | ||
| Do | Investors could emerge from Neil Woodford debacle with £1B loss, internal analysis reveals |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
